• Explore /
  • Poster
  • / A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study).

A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study).

Abstract Poster

Authors

null

Shinji Nakamichi

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan

Shinji Nakamichi , Kaoru Kubota , Toshihiro Misumi , Shuji Murakami , Tetsuro Kondo , Isamu Okamoto , Koichi Minato , Daijiro Harada , Kazutoshi Isobe , Hidetoshi Itani , Saori Takata , Hiroshi Wakui , Yuki Misumi , Satoshi Ikeda , Tetsuhiko Asao , Takeo Inoue , Shinobu Hosokawa , Yumiko Kobayashi , Yuichi Takiguchi , Hiroaki Okamoto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Clinical Trial Registration Number

jRCTs031190117

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8536)

DOI

10.1200/JCO.2022.40.16_suppl.8536

Abstract #

8536

Poster Bd #

163

Abstract Disclosures

Similar Posters

First Author: John M. Varlotto

First Author: David R. Spigel

First Author: Yi-Long Wu

First Author: Steven H. Lin